This Article Full Text Full Text (PDF) All Versions of this Article: 200302-248OCv1 168/10/1227    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Terheggen-Lagro, S. W. Articles by van der Ent, C. K. Search for Related Content PubMed PubMed Citation Articles by Terheggen-Lagro, S. W. Articles by van der Ent, C. K.

End-Tidal Carbon Monoxide Corrected for Lung Volume Is Elevated in Patients with Cystic Fibrosis

Department of Pediatric Pulmonology, University Medical Center, Utrecht, The Netherlands; and Department of Pediatrics, Stanford University Medical Center, Stanford, California

Correspondence and requests for reprints should be addressed to Suzanne W. Terheggen-Lagro, M.D., Department of Pediatric Pulmonology, University Medical Center, Internal Postal Code KH 01.419.0, PO-Box 85090 3508, AB Utrecht, The Netherlands. E-mail: s.terheggen{at}wkz.azu.nl

Several factors influence levels of end-tidal carbon monoxide (ETCO). We studied determinants of ETCO corrected for inhaled CO (ETCOc) levels in healthy control subjects and compared ETCOc levels and determinants between healthy control subjects and patients with cystic fibrosis (CF). Thirty healthy control subjects (mean ± SD age, 23 ± 6 years) and twenty clinically stable patients with CF, aged 13.5 ± 3.5 years were included. ETCO was measured with the CO-STAT End-Tidal Breath Analyzer (Natus Medical, Inc., San Carlos, CA), and determinants included lung volume (measured with the multiple-breath helium wash-in method), CO-diffusion capacity, and different expiratory flow rates. In healthy control subjects we found a significant correlation between ETCOc and lung volume (r = 0.64, p < 0.05) and with CO-diffusion capacity uncorrected for VA (r = 0.48, p = 0.02). There was no expiratory flow rate dependency in either group. Patients with CF showed no difference in ETCOc levels compared with control subjects (mean 1.2 ± 0.4 ppm vs. 1.3 ± 0.4 ppm, p = 0.32), but patients with CF had lower total lung capacity–helium than healthy control subjects. ETCOc corrected for lung volume was significantly higher in patients with CF compared with control subjects (p < 0.001). We hypothesize that a possible increase in breath CO caused by airway inflammation might be masked by differences in lung volumes between control subjects and patients with CF.

Key Words: ETCOc • inflammatory marker • lung volume • cystic fibrosis

This article has been cited by other articles:

				M. J. Tobin Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2003 Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 277 - 287. [Full Text] [PDF]